Scotts Miracle-Gro (SMG) was very actively spoken about on its foray into the cannabis industry. However, unlike Canopy Growth (WEED), Aurora Cannabis (ACB), and Aphria (APHA), SMG was not directly into the cultivation business (HMMJ). Let’s look at how the analysts view the stock over the next 12 months.
In February, analysts’ consensus recommendation for Scotts Miracle-Gro Company was a “buy.” The overall recommendation month-over-month from seven analysts remained largely unchanged. Among the seven analysts, one recommended a “strong buy,” while three recommended a “buy” on the stock. Also, three analysts recommended a “hold” on the company while none had a “sell” recommendation for SMG in the month of February.
The consensus target price for Scotts Miracle-Gro Company in February increased month-over-month at $85.5 from $82.5. on February 21, Scotts Miracle-Gro Company closed at $80 which would leave an upside of just about 5.8% if the prices were to converge over the next 12 month period.
SMG stock has struggled over the past few years. The stock missed earnings estimate for four of the five recent quarters which certainly is concerning for investors. This essentially means that the company underperformed analysts’ expectations on four of the recent five earnings release.
For ongoing updates, visit Market Realist’s Healthcare page.